Skip to main content
COSMO Pharmaceuticals N.V. logo

COSMO Pharmaceuticals N.V. — Investor Relations & Filings

Ticker · COPN ISIN · NL0011832936 LEI · 724500OX0EBQRYTVV639 SW Manufacturing
Open in API
Filings indexed 173 across all filing types
Latest filing 2026-06-15 Regulatory Filings
Country NL Netherlands
Listing SW COPN

About COSMO Pharmaceuticals N.V.

https://www.cosmopharma.com/

COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products in gastroenterology, dermatology, and healthtech. The company's portfolio is built around its proprietary MMX® technology, a platform for the targeted delivery of active ingredients in the colon. Key products include GI Genius™, an AI-powered device for endoscopy; Winlevi®, a topical treatment for acne; and therapies for inflammatory bowel diseases such as Lialda®/Mezavant® and Uceris®/Cortiment®. In addition to its own product pipeline, Cosmo provides contract manufacturing services, including process assessment, technology transfer, stability testing, and market release for pharmaceutical products.

Recent filings

Filing Released Lang Actions
Cosmo welcomes the launches of Winlevi® in Austria and Germany
Regulatory Filings Classification · 95% confidence The document is a press release announcing the commercial launch of Cosmo's acne treatment Winlevi® in Austria and Germany. It discusses product details, partnerships, and regulatory approvals but does not contain financial results, detailed financial data, or management commentary on financial performance. The length is about 4,632 characters, which aligns with a typical press release or announcement. It includes a mention of the upcoming Half-Year 2026 Results and Report on 23 July 2026, indicating this is not that financial report itself. There are no indications this is an earnings release (ER) or an investor presentation (IP), nor detailed management discussion (MDA). It also is not related to legal proceedings, financing, or governance changes. It primarily serves as a general company announcement regarding product launch and market expansion, fitting best under Regulatory Filings (RNS) which acts as a catch-all for company announcements outside other defined categories.
2026-06-15 English
Cosmo freut sich über die Markteinführungen von Winlevi® in Österreich und Deutschland
Regulatory Filings Classification · 95% confidence The document is a press release about the product launch of Winlevi® in Austria and Germany by Cosmo N.V. It contains no financial statements, analysis, regulatory certifications, or detailed financial results. It does not present annual, quarterly, or auditing reports, nor does it discuss shareholder votes, dividends, or corporate governance changes. The text focuses solely on operational news regarding product market introduction and company background. The length (5118 characters) is above the short threshold but the content clearly indicates a corporate announcement rather than any financial filing or report. There is no indication it is an announcement relating to a report publication or a regulatory filing of official nature. Therefore, the document best fits into the 'Regulatory Filings' category as a general regulatory announcement or corporate news that does not fit into other specific categories.
2026-06-15 German
Cosmo welcomes the Launch of Winlevi® in Key European Markets by its Partner Glenmark
Regulatory Filings Classification · 79% confidence The document is a corporate press release announcing the commercial launch of a pharmaceutical product (Winlevi®) in European markets by Cosmo and its partner. It does not present financial statements, meeting materials, voting results, or any formal regulatory form. It is not an earnings release, shareholder vote declaration, or management change notice, nor does it detail scheduled report publication beyond a one‐line financial calendar entry. As it is a general corporate announcement, it falls into the fallback category for miscellaneous regulatory communications (RNS).
2026-06-11 English
Cosmo begrüsst die Markteinführung von Winlevi® in wichtigen europäischen Märkten durch seinen Partner Glenmark
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing the commercial launch of Winlevi® in European markets. It contains no financial statements, regulatory filings, proxy materials, or meeting/voting information, nor does it announce an upcoming report publication. This type of miscellaneous corporate communication falls under general regulatory announcements. Therefore, the most appropriate category is Regulatory Filings (RNS).
2026-06-11 German
Cosmo Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program
Regulatory Filings Classification · 12% confidence The document is a corporate press release announcing the completion of patient enrolment in a Phase II clinical trial. It contains no financial statements, no management or board changes, no dividend or financing details, and it is not a request for votes or a regulatory certification. It is a miscellaneous corporate announcement that does not fit any specific category, so it defaults to Regulatory Filings (RNS).
2026-05-18 English
Cosmo gibt Abschluss der Patientenrekrutierung für Phase-II-Studie des Programms zur Behandlung von distaler Colitis ulcerosa bekannt
Regulatory Filings Classification · 73% confidence The document is a corporate press release announcing the completion of patient recruitment for a Phase-II clinical trial. It does not contain financial statements or results, nor is it an AGM, earnings release, management change, or any other specialized filing. It is not introducing a new report publication, but rather providing operational/clinical program news. Therefore, it best fits the fallback category for general corporate/regulatory announcements.
2026-05-18 German

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.